)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
SOBI
SOBI (SOBI) investor relations material
SOBI Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
Q3 revenue rose 16% at CER to SEK 9,124M; excluding seasonal RSV royalties, portfolio growth was 26%. Nine-month revenue increased 23% at CER to SEK 24,150M.
Strategic portfolio revenue grew 25% at CER to SEK 6,298M; launches and international markets supported momentum.
Financial highlights
Q3 revenue was SEK 9,124M versus SEK 7,776M, up 17% at actual exchange rates.
Adjusted gross profit was SEK 7,195M, up 16%; adjusted gross margin was 79% versus 80%.
Adjusted EBITA was SEK 4,087M, up 11%; margin was 45% versus 47%.
Profit for the period was SEK 2,349M versus a loss of SEK 2,895M; diluted EPS was SEK 6.69 versus negative SEK 8.32.
Operating cash flow was SEK 1,871M, up 2%.
Outlook and guidance
FY26 revenue growth guidance rose to high-teens to low-20s% at CER from mid- to high-teens; adjusted EBITA margin guidance remains mid- to high-30s%.
Tryngolza’s European launch is expected earlier in 2027 than planned, following a positive CHMP opinion; an EU decision was expected in Q4 2026.
Launch preparation and the Gamifant sepsis trial remain investment priorities; some NASP launch costs shifted to 2027, balanced by cost controls and resource reallocation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SOBI
- Once-weekly efanesoctocog alfa showed strong bleed control across ages and care settings.SOBI
Status Update - Upgraded guidance and robust growth reflect successful launches and expanding pipeline.SOBIMorgan Stanley 24th Annual Global Healthcare Conference
- Rapid growth, major launches, and global expansion set the stage for doubling revenue by 2030.SOBIInvestor presentation
- Strong H1 growth, major launches, and pipeline advances set the stage for ambitious 2030 targets.SOBISEB Nordic Large Cap Seminar presentation
- Q2 2026 revenue up 29% at CER, 35% EBITA margin, and outlook raised on strong pipeline and portfolio.SOBIQ2 2026
- Strong 2025 revenue and margin growth driven by strategic launches and pipeline progress.SOBIQ4 2025
- Q3 2025 saw 21% CER revenue growth, 47% margin, and upgraded 2025 guidance.SOBIQ3 2025
- Strategic portfolio growth and robust margins drive strong Q1 2025 results and outlook.SOBIQ1 2025
- Revenue grew 19% in 2024, with strong launches and pipeline driving 2025 growth outlook.SOBIQ4 2024
Next SOBI earnings date
Q4 20264 Feb, 2027
SOBI
Next SOBI earnings date
Q4 20264 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Swedish Orphan Biovitrum AB, an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. The company operates through three segments: Haemophilia & Hereditary Diseases, Inflammation & Immunology, and Other. It offers Alprolix for hemophilia B; Elocta to treat hemophilia A; Doptelet for thrombocytopenia; Kineret for rheumatoid arthritis; Thiola for cystinuria; Xultophy Cartridge that is used with Flexpen for treatment of diabetes; and Velphoro for hyperphosphatemia.